Skip to main content
SpringerLink
Log in

Standard and Novel Therapeutic Approaches to Behçet’s Disease

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Behçet’s disease (BD), a systemic inflammatory disorder of unknown aetiology, is characterised by recurrent attacks of oral aphthous ulcers, genital ulcers, skin lesions, uveitis or other manifestations affecting the blood vessels, gastrointestinal tract, and respiratory and central nervous systems. Although the treatment of BD is empirical, in recent years, it has been shown that early and effective treatment of acute inflammatory lesions and prevention of relapses can help to reduce the disease burden and improve outcome. Randomised, controlled trials are limited in BD, but those that have been conducted have documented favourable effects of colchicine, ciclosporin, azathioprine, thalidomide, dapsone, depot methylprednisolone, rebamipide, sucralfate, benzathine benzylpenicillin, interferon-α-2a and etanercept for various BD manifestations. Anti-inflammatory and/or immunosuppressive treatments should be tailored according to the disease severity and prognostic factors. More potent drugs, such as azathioprine, ciclosporin, interferon-α and infliximab, are effective in the suppression of more severe systemic features as well as mucocutaneous manifestations of BD. Although no randomised, controlled trials are yet available, results of open studies with both interferon-α and infliximab are promising for those patients with disease resistant to conventional immunosuppressive treatments. Multicentre, multi-disciplinary and long-term trials aiming to assess the efficacy of interventions in both the treatment of acute inflammatory attacks and the prevention of relapses are required in order to provide more generalisable results that can lead to better management plans.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Sakane T, Takeno M, Suzuki N, et al. Behçet’ s disease. N Engl J Med 1999 Oct 21; 341(17): 1284–91

    Article  PubMed  CAS  Google Scholar 

  2. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003 Jan; 82(1): 60–76

    Article  Google Scholar 

  3. Yazici H, Tuzun Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis 1984 Dec; 43(6): 783–9

    Article  PubMed  CAS  Google Scholar 

  4. Gul A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Behçet’s disease. Rheumatology (Oxford) 2001 Jun; 40(6): 668–72

    Article  CAS  Google Scholar 

  5. Gul A. Behçet’s disease: an update on the pathogenesis. Clin Exp Rheumatol 2001 Sep–Oct; 19 (5 Suppl. 24): S6–12

    PubMed  CAS  Google Scholar 

  6. Gul A. Behçet’s disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005 Feb; 4(1): 81–3

    Article  PubMed  Google Scholar 

  7. International Study Group for Behçet’s disease. Criteria for diagnosis of Behçet’s disease. Lancet 1990 May 5; 335(8697): 1078–80

    Google Scholar 

  8. The International Study Group for Behçet’s disease. Evaluation of diagnostic (‘classification’) criteria in Behçet’s disease: towards internationally agreed criteria. Br J Rheumatol 1992 May; 31(5): 299–308

    Article  Google Scholar 

  9. Akman-Demir G, Baykan-Kurt B, Serdaroglu P, et al. Seven-year follow-up of neurologic involvement in Behçet syndrome. Arch Neurol 1996 Jul; 53(7): 691–4

    Article  PubMed  CAS  Google Scholar 

  10. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004 Sep; 138(3): 373–80

    Article  PubMed  Google Scholar 

  11. Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med 2004 Dec 1; 117(11): 867–70

    Article  PubMed  Google Scholar 

  12. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 1997 Apr; 40(4): 769–74

    Article  PubMed  CAS  Google Scholar 

  13. Saenz A, Ausejo M, Shea B, et al. Pharmacotherapy for Behçet’s syndrome. Cochrane Database Syst Rev 2000; (2): CD001084

  14. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum 2001 Nov; 44(11): 2686–92

    Article  PubMed  CAS  Google Scholar 

  15. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum 2005 Aug; 52(8): 2478–84

    Article  PubMed  CAS  Google Scholar 

  16. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet’s disease with refractory uveoretinitis. J Rheumatol 2004 Jul; 31(7): 1362–8

    PubMed  CAS  Google Scholar 

  17. Rosenbaum JT. Blind insight: eyeing anti-tumor necrosis factor treatment in uveitis associated with Behçet’s disease. J Rheumatol 2004 Jul; 31(7): 1241–3

    PubMed  CAS  Google Scholar 

  18. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 1990 Feb 1; 322(5): 281–5

    Article  PubMed  CAS  Google Scholar 

  19. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet 1989 May 20; I(8647): 1093–6

    Article  Google Scholar 

  20. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behçet’s disease. Haematologica 1980 Jun; 65(3): 399–402

    PubMed  CAS  Google Scholar 

  21. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998 Mar 15; 128(6): 443–50

    PubMed  CAS  Google Scholar 

  22. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study. J Dermatol 2002 May; 29(5): 267–79

    PubMed  CAS  Google Scholar 

  23. Mat C, Yurdakul S, Uysal S, et al. A double-blind trial of depot corticosteroids in Behçet’s syndrome. Rheumatology (Oxford) 2006 Mar; 45(3): 348–52

    Article  CAS  Google Scholar 

  24. Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behçet’s syndrome: a randomized double-blind trial. Br J Rheumatol 1988 Aug; 27(4): 300–2

    Article  PubMed  CAS  Google Scholar 

  25. Moral F, Hamuryudan V, Yurdakul S, et al. Inefficacy of azapropazone in the acute arthritis of Behçet’s syndrome: a randomized, double blind, placebo controlled study. Clin Exp Rheumatol 1995 Jul–Aug; 13(4): 493–5

    PubMed  CAS  Google Scholar 

  26. Calguneri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet’s disease: a randomized clinical trial. Arthritis Rheum 1996 Dec; 39(12): 2062–5

    Article  PubMed  CAS  Google Scholar 

  27. Matsuda T, Ohno S, Hirohata S, et al. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet’s disease: a randomised, double-blind, placebo-controlled study. Drugs R D 2003; 4(1): 19–28

    Article  PubMed  CAS  Google Scholar 

  28. Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol 1999 May; 135(5): 529–32

    Article  PubMed  CAS  Google Scholar 

  29. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002 Apr; 138(4): 467–71

    Article  PubMed  CAS  Google Scholar 

  30. Hamuryudan V, Yurdakul S, Rosenkaimer F, et al. Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behçet’s syndrome: a randomized, double blind trial. Br J Rheumatol 1991 Oct; 30(5): 395–6

    Article  PubMed  CAS  Google Scholar 

  31. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol 2005 Jan; 32(1): 98–105

    PubMed  CAS  Google Scholar 

  32. Barnes CG. Treatment of Behçet’s syndrome. Rheumatology (Oxford) 2006 Mar; 45(3): 245–7

    Article  CAS  Google Scholar 

  33. Kim EC, Foster CS. Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use. Int Ophthalmol Clin 2006; 46(2): 141–64

    Article  PubMed  Google Scholar 

  34. Jabs DA, Rosenbaum JT. Guidelines for the use of immunosup-pressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001 May; 131(5): 679

    Article  PubMed  CAS  Google Scholar 

  35. Karacorlu M, Mudun B, Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol 2004 Aug; 138(2): 289–91

    Article  PubMed  CAS  Google Scholar 

  36. Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991 Aug 15; 112(2): 138–46

    PubMed  CAS  Google Scholar 

  37. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003 Apr; 87(4): 423–31

    Article  PubMed  CAS  Google Scholar 

  38. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 2001 Jul 28; 358(9278): 295–6

    Article  PubMed  CAS  Google Scholar 

  39. Erkan F, Gul A, Tasali E. Pulmonary manifestations of Behçet’s disease. Thorax 2001 Jul; 56(7): 572–8

    Article  PubMed  CAS  Google Scholar 

  40. Yazici H, Yurdakul S, Hamuryudan V. The management of Behçet’s syndrome: how are we doing? Clin Exp Rheumatol 1999 Mar–Apr; 17(2): 145–7

    PubMed  CAS  Google Scholar 

  41. Zierhut M, Mizuki N, Ohno S, et al. Immunology and functional genomics of Behçet’s disease. Cell Mol Life Sci 2003 Sep; 60(9): 1903–22

    Article  PubMed  CAS  Google Scholar 

  42. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, et al. Neovascularization of the optic disc in Behçet’s disease. Jpn J Ophthalmol 2006 May–Jun; 50(3): 256–65

    Article  PubMed  Google Scholar 

  43. Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behçet’s disease. Ocul Immunol Inflamm 2001 Dec; 9(4): 219–29

    Article  PubMed  CAS  Google Scholar 

  44. Mamo JG. Treatment of Behçet disease with chlorambucil: a follow-up report. Arch Ophthalmol 1976 Apr; 94(4): 580–3

    Article  PubMed  CAS  Google Scholar 

  45. Mochizuki M, Masuda K, Sakane T, et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet’s disease: Japanese FK 506 Study Group on Refractory Uveitis. Transplant Proc 1991 Dec; 23(6): 3343–6

    PubMed  CAS  Google Scholar 

  46. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol. Epub 2006 May 4

  47. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004 Mar 2; 140(5): 404–6

    PubMed  CAS  Google Scholar 

  48. Pervin K, Childerstone A, Shinnick T, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behçet’s disease. J Immunol 1993 Aug 15; 151(4): 2273–82

    PubMed  CAS  Google Scholar 

  49. Hasan A, Fortune F, Wilson A, et al. Role of gamma delta T cells in pathogenesis and diagnosis of Behçet’s disease. Lancet 1996 Mar 23; 347(9004): 789–94

    Article  PubMed  CAS  Google Scholar 

  50. Phipps PA, Stanford MR, Sun J-B, et al. Prevention of mucosally induced uveitis with a HSP60-derived peptide linked to cholera toxin B subunit. Eur J Immunol 2003; 33: 224–32

    Article  PubMed  CAS  Google Scholar 

  51. Stanford M, Whittall T, Bergmeier LA, et al. Oral tolerization with peptide 336–351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behçet’s disease. Clin Exp Immunol 2004 Jul; 137(1): 201–8

    Article  PubMed  CAS  Google Scholar 

  52. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 1999 Mar; 106(3): 586–9

    Article  PubMed  CAS  Google Scholar 

  53. Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999 May; 246(5): 339–46

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. Dr Gul has received speaker’s honoraria from Schering-Plough, Wyeth and Abbott; travel grants from Schering-Plough, Novartis, Wyeth and Abbott; and investigator-initiated drug trial support from Schering-Plough.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Capa, 34390, Istanbul, Turkey

    Ahmet Gul

Authors
  1. Ahmet Gul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ahmet Gul.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gul, A. Standard and Novel Therapeutic Approaches to Behçet’s Disease. Drugs 67, 2013–2022 (2007). https://doi.org/10.2165/00003495-200767140-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767140-00004

Keywords

Search

Navigation